AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12427785 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v (Proviva) administered orally for at least one week preoperatively and postoperatively
Number of subjects: 129
Study 10488954 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitostanol ester margarine
Number of subjects: 151
Study 10488954 — intervention group
Group type: COMPARATOR
Intervention: Control (home diet)
Number of subjects: 151
Study 8942421 — intervention group
Group type: COMPARATOR
Intervention: Oat bran diet
Number of subjects: 23
Study 8942421 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amylose starch diet
Number of subjects: 23
Study 1757595 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant stimulus condition (same audiotape presented for three weeks)
Number of subjects: 5
Study 1757595 — intervention group
Group type: COMPARATOR
Intervention: Variable stimulus condition (different audiotape presented each session)
Number of subjects: 5
Study 7051247 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP)
Number of subjects: 30
Study 7051247 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 30
Study 7051247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31834418 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified arthroscopic approach (group B)
Number of subjects: 11
Study 31834418 — intervention group
Group type: COMPARATOR
Intervention: Open tibial inlay technique (group A)
Number of subjects: 11
Study 30664882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous scorpion antivenom
Number of subjects: 100
Study 30664882 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular scorpion antivenom
Number of subjects: 100
Study 28433371 — intervention group
Group type: EXPERIMENTAL
Intervention: PGD‐A group (preimplantation genetic diagnosis for aneuploidy screening)
Number of subjects: 205
Study 28433371 — intervention group
Group type: EXPERIMENTAL
Intervention: PGD‐A group
Number of subjects: 205
Study 28433371 — intervention group
Group type: COMPARATOR
Intervention: Control group (blastocyst transfer without PGD‐A)
Number of subjects: 205
Study 28433371 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 205
Study 28095373 — intervention group
Group type: EXPERIMENTAL
Intervention: Field MAL‐PDT (FT side)
Number of subjects: 0
Study 28095373 — intervention group
Group type: COMPARATOR
Intervention: Lesion‐by‐lesion MAL‐PDT (LT side)
Number of subjects: 0
Study 26474438 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively demanding physical education lesson consisting of different coordinative exercises
Number of subjects: 90
Study 26474438 — intervention group
Group type: COMPARATOR
Intervention: Normal sedentary school lesson
Number of subjects: 90
Study 23203544 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-pump (MP) administration of epirubicin for 48 hours
Number of subjects: 11
Study 23203544 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous drip (ID) administration of epirubicin for 1 hour
Number of subjects: 11
Study 20064862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough trick technique (single 'warm-up' cough followed by a second cough coinciding with needle puncture)
Number of subjects: 68
Study 20064862 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard immunization procedure without cough trick)
Number of subjects: 68
Study 20064862 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction measure for older participants and nurses
Number of subjects: 68
Study 17510682 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 FA supplementation alone (FO, n=10)
Number of subjects: 22
Study 17510682 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 FA supplementation plus exercise training (FO+ExTr, n=12)
Number of subjects: 22
Study 17510682 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 22
Study 15789189 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11870119 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 37
Study 11870119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 10076899 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta power during haptic exploration
Number of subjects: 0
Study 10076899 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta power
Number of subjects: 0
Study 7671838 — intervention group
Group type: EXPERIMENTAL
Intervention: Molded heterograft tympanic membrane
Number of subjects: 25
Study 7671838 — intervention group
Group type: COMPARATOR
Intervention: Autograft (implied as control)
Number of subjects: 25
Study 2188217 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive discharge planning protocol implemented by a gerontological nurse specialist
Number of subjects: 0
Study 2188217 — intervention group
Group type: COMPARATOR
Intervention: Hospital's general discharge planning procedure
Number of subjects: 0
Study 6652009 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 60
Study 6652009 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 60
Study 6652009 — intervention group
Group type: COMPARATOR
Intervention: Control (non-pregnant patients)
Number of subjects: 60
Study 31736025 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with 20 ml 0.25 % bupivacaine (10 ml for each level) preoperatively
Number of subjects: 50
Study 31736025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study 28941314 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 30
Study 28941314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27100333 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (dose = 160 mg) administered in various conditions (coffee vs energy drink, different rates of consumption, and temperature)
Number of subjects: 24
Study 27100333 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (dose = 160 mg) administered in coffee
Number of subjects: 24
Study 27100333 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (dose = 160 mg) administered in energy drink
Number of subjects: 24
Study 25145375 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative tobacco products (ATPs) including e-cigarettes, little cigars/cigarillos, hookah, other smokeless tobacco products, chewing tobacco/moist snuff
Number of subjects: 292
Study 25145375 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning to quit smoking in the next 30 days
Number of subjects: 292
Study 25145375 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime e-cigarette users
Number of subjects: 292
Study 21659626 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/HCT 300/25 mg SPC
Number of subjects: 0
Study 21659626 — intervention group
Group type: COMPARATOR
Intervention: Free combination of aliskiren and HCT
Number of subjects: 0
Study 21659626 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) alone
Number of subjects: 0
Study 21659626 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (when administered with HCT)
Number of subjects: 0
Study 19560111 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 61
Study 19560111 — intervention group
Group type: COMPARATOR
Intervention: mepivacaine
Number of subjects: 61
Study 20688256 — intervention group
Group type: EXPERIMENTAL
Intervention: AG5
Number of subjects: 91
Study 20688256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 16142255 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow scintigraphy (BMS) with 99mTc‐sulphur‐colloid
Number of subjects: 47
Study 16142255 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow biopsy (BMB)
Number of subjects: 47
Study 12147533 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PTCA VBT with Sr90
Number of subjects: 30
Study 9663913 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated oscillometric device
Number of subjects: 400
Study 9663913 — intervention group
Group type: COMPARATOR
Intervention: Aneroid sphygmomanometer
Number of subjects: 400
Study 7923656 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 2231
Study 7923656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2231
Study 3044181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (20 mg)
Number of subjects: 60
Study 3044181 — intervention group
Group type: EXPERIMENTAL
Intervention: Piritramide (15 mg)
Number of subjects: 60
Study 3044181 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 60
Study 30088425 — intervention group
Group type: EXPERIMENTAL
Intervention: NGAL test result provided to doctors for risk assessment
Number of subjects: 0
Study 26820419 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 24
Study 26820419 — intervention group
Group type: COMPARATOR
Intervention: No treatment (off MPH)
Number of subjects: 24
Study 24150547 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 24150547 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 24150547 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Propofol and Sevoflurane)
Number of subjects: 30
Study 22451320 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 120
Study 22451320 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Interaction
Number of subjects: 120
Study 22451320 — intervention group
Group type: COMPARATOR
Intervention: Walking
Number of subjects: 120
Study 22451320 — intervention group
Group type: COMPARATOR
Intervention: No Intervention
Number of subjects: 120
Study 20833444 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (intermittent therapy)
Number of subjects: 138
Study 20833444 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (blinded)
Number of subjects: 138
Study 20833444 — intervention group
Group type: COMPARATOR
Intervention: Placebo (blinded)
Number of subjects: 138
Study 18500561 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized tablet (M-7) containing chitosan and hydroxypropyl methylcellulose phthalate
Number of subjects: 0
Study 18500561 — intervention group
Group type: COMPARATOR
Intervention: Marketed tablet
Number of subjects: 0
Study 15705006 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Treatment (BT)
Number of subjects: 72
Study 15705006 — intervention group
Group type: COMPARATOR
Intervention: Usual Clinical Care (UC)
Number of subjects: 72
Study 15705006 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Treatment (BT) (post hoc analysis)
Number of subjects: 72
Study 15705006 — intervention group
Group type: COMPARATOR
Intervention: Usual Clinical Care (UC) (post hoc analysis)
Number of subjects: 72
Study 15705006 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Treatment (BT) (week 14)
Number of subjects: 72
Study 15705006 — intervention group
Group type: COMPARATOR
Intervention: Usual Clinical Care (UC) (week 14)
Number of subjects: 72
Study 12852711 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g PLT 3514 emulsion (0.75 g GLA + 0.5 g EPA)
Number of subjects: 43
Study 12852711 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g PLT 3514 emulsion (1.13 g GLA + 0.75 g EPA)
Number of subjects: 43
Study 12852711 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil) emulsion
Number of subjects: 43
Study 10494189 — intervention group
Group type: EXPERIMENTAL
Intervention: First line treatment for Hodgkin's disease
Number of subjects: 0
Study 10494189 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with autologous stem cell support
Number of subjects: 0
Study 8975400 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg orally three times a day for seven days
Number of subjects: 80
Study 8975400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 8975400 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 80
Study 1686733 — intervention group
Group type: EXPERIMENTAL
Intervention: salmon calcitonin (sCT) 100 MRC units, im
Number of subjects: 6
Study 1686733 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study 6140261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg and 2 mg)
Number of subjects: 10
Study 6140261 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (5 mg and 10 mg)
Number of subjects: 10
Study 6140261 — intervention group
Group type: COMPARATOR
Intervention: Clorazepate (7.5 mg and 15 mg)
Number of subjects: 10
Study 6140261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31345971 — intervention group
Group type: EXPERIMENTAL
Intervention: HBCPs' programme
Number of subjects: 0
Study 31345971 — intervention group
Group type: EXPERIMENTAL
Intervention: HBCPs' programme + mobile health application
Number of subjects: 0
Study 31345971 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 30261125 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-amount, low-intensity exercise (180 kcal/session for women, 300 kcal/session for men at 50% VO2 peak)
Number of subjects: 103
Study 30261125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amount, low-intensity exercise (HALI; 360 kcal/session for women, 600 kcal/session for men at 50% VO2 peak)
Number of subjects: 103
Study 30261125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amount, high-intensity exercise (HAHI; 360 kcal/session for women, 600 kcal/session for men at 75% VO2 peak)
Number of subjects: 103
Study 30261125 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study 26372680 — intervention group
Group type: COMPARATOR
Intervention: Serum chitotriosidase and YKL-40 levels in patients with asthma and COPD
Number of subjects: 233
Study 26372680 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype and age effects on YKL-40 and chitotriosidase activity
Number of subjects: 233
Study 26372680 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exacerbations, allergen-induced airway obstruction, and corticosteroid treatment
Number of subjects: 233
Study 26372680 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen inhalation effects on blood and sputum YKL-40 levels
Number of subjects: 233
Study 24779524 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record-based transitional care intervention
Number of subjects: 3671
Study 24779524 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3671
Study 22313688 — intervention group
Group type: EXPERIMENTAL
Intervention: Triumph(®) triclosan eluting stent
Number of subjects: 20
Study 22313688 — intervention group
Group type: COMPARATOR
Intervention: Percuflex Plus(®) non-eluting stent (control)
Number of subjects: 20
Study 21149331 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 389
Study 21149331 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 389
Study 21149331 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (10 years increase)
Number of subjects: 389
Study 21149331 — intervention group
Group type: EXPERIMENTAL
Intervention: Race (African Americans vs Caucasians and Hispanics)
Number of subjects: 389
Study 21149331 — intervention group
Group type: EXPERIMENTAL
Intervention: Location (Rectum vs Right Colon)
Number of subjects: 389
Study 18058479 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine maleate 10 mg
Number of subjects: 24
Study 18058479 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate 10 mg (Norvasc)
Number of subjects: 24
Study 18058479 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine maleate and besylate (both)
Number of subjects: 24
Study 16118338 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (E2) supplementation (2 mg/d for 8 days)
Number of subjects: 11
Study 16118338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11222360 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic graft-versus-host disease (GVHD) management strategies
Number of subjects: 0
Study 9641502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin
Number of subjects: 51
Study 9641502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 7584302 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who participated in the event three times in a spatial condition.
Number of subjects: 37
Study 7584302 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who participated in the event one time in a spatial condition.
Number of subjects: 37
Study 7584302 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who participated in the event one or three times in a nonspatial condition.
Number of subjects: 37
Study 7584302 — intervention group
Group type: COMPARATOR
Intervention: Control group (same-aged controls).
Number of subjects: 37
Study 2680790 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-drug therapy (Adriablastine, Cisplatin, Cyclophosphamide)
Number of subjects: 48
Study 2680790 — intervention group
Group type: COMPARATOR
Intervention: Two-drug chemotherapy without Cisplatin
Number of subjects: 48
Study 988458 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximethasone 0.25%
Number of subjects: 26
Study 988458 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide 0.10%
Number of subjects: 26
Study 31155896 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal fistulotomy and marsupialisation of the edges of the laid open track
Number of subjects: 60
Study 31155896 — intervention group
Group type: COMPARATOR
Intervention: Anal fistulotomy
Number of subjects: 60
Study 29296598 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling program by a midwife during three sessions
Number of subjects: 90
Study 29296598 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 90
Study 29296598 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling program by a midwife
Number of subjects: 90
Study 26294693 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling kit (n=1000)
Number of subjects: 2000
Study 26294693 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling kit and £5 voucher on return of sample (n=500)
Number of subjects: 2000
Study 26294693 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling kit on request (n=500)
Number of subjects: 2000
Study 24086352 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic Q‐potencies (case history I)
Number of subjects: 44
Study 24086352 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic Q‐potencies (case history II)
Number of subjects: 44
Study 24086352 — intervention group
Group type: EXPERIMENTAL
Intervention: Case history I (homeopathic Q‐potencies)
Number of subjects: 44
Study 24086352 — intervention group
Group type: COMPARATOR
Intervention: Placebo (case history I)
Number of subjects: 44
Study 24086352 — intervention group
Group type: COMPARATOR
Intervention: Placebo (case history II)
Number of subjects: 44
Study 24086352 — intervention group
Group type: EXPERIMENTAL
Intervention: Case history II (homeopathic Q‐potencies)
Number of subjects: 44
Study 21377075 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB)
Number of subjects: 64
Study 21377075 — intervention group
Group type: COMPARATOR
Intervention: Control group (IV PCA with fentanyl)
Number of subjects: 64
Study 21330795 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face collaborative learning in triads (N = 12)
Number of subjects: 47
Study 21330795 — intervention group
Group type: COMPARATOR
Intervention: Individual learning (N = 11)
Number of subjects: 47
Study 17353040 — intervention group
Group type: EXPERIMENTAL
Intervention: C-ACT (Childhood Asthma Control Test)
Number of subjects: 343
Study 17353040 — intervention group
Group type: EXPERIMENTAL
Intervention: C-ACT
Number of subjects: 343
Study 15072210 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of R-R time series including criteria for PAC, atrial bigeminy, trigeminy, and short runs of paroxysmal atrial tachycardia
Number of subjects: 0
Study 12186498 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analogues (SM-a), including octreotide (OCT) and lanreotide (LRT)
Number of subjects: 30
Study 12186498 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin analogues (SM-a)
Number of subjects: 30
Study 12186498 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study 12186498 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy individuals)
Number of subjects: 30
Study 9118661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (60 mg initially followed by two doses of 30 mg at 8-hr intervals)
Number of subjects: 27
Study 9118661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7680457 — intervention group
Group type: EXPERIMENTAL
Intervention: Apex electrode positive
Number of subjects: 289
Study 7680457 — intervention group
Group type: COMPARATOR
Intervention: Apex electrode negative
Number of subjects: 289
Study 2949285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin 2 g administered once
Number of subjects: 60
Study 2949285 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin 4 g administered once
Number of subjects: 60
Study 30935865 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 97
Study 29406486 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos with text messages
Number of subjects: 90
Study 29406486 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos-only
Number of subjects: 90
Study 29406486 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages-only
Number of subjects: 90
Study 29406486 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 26349552 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin plus flucloxacillin (combination group)
Number of subjects: 60
Study 26349552 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (standard therapy group)
Number of subjects: 60
Study 26349552 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (vancomycin)
Number of subjects: 60